Is losartan good for kidneys
Pro Research Analysisby 
Searched over 200M research papers
The Renoprotective Effects of Losartan: A Comprehensive Review
Introduction to Losartan and Kidney Health
Losartan, an angiotensin II receptor blocker (ARB), is widely used to manage hypertension and protect kidney function, particularly in patients with diabetes and chronic kidney disease (CKD). This article synthesizes findings from multiple studies to evaluate the efficacy of losartan in preserving renal health.
Losartan in Diabetic Nephropathy
Type 2 Diabetes and Nephropathy
Diabetic nephropathy is a leading cause of end-stage renal disease (ESRD). A pivotal study involving 1513 patients with type 2 diabetes and nephropathy demonstrated that losartan significantly reduced the risk of doubling serum creatinine levels and the incidence of ESRD by 25% and 28%, respectively, compared to placebo . Additionally, losartan decreased proteinuria by 35%, indicating its strong renoprotective effects beyond blood pressure control .
Early Diabetic Kidney Disease
In a 6-year clinical trial with American Indians with type 2 diabetes, losartan showed potential in preserving kidney structure, particularly in patients with microalbuminuria. The study found that losartan treatment resulted in lower mesangial fractional volume, a marker of kidney damage, compared to placebo . However, long-term follow-up indicated no significant difference in the decline of glomerular filtration rate (GFR) between the losartan and placebo groups, suggesting that early benefits may not extend over a prolonged period .
Losartan in Chronic Kidney Disease
Comparative Studies with Other Treatments
A study comparing losartan to the calcium channel blocker amlodipine in patients with CKD and hypertension found that losartan significantly reduced proteinuria over 12 months, whereas amlodipine did not . This reduction in proteinuria is crucial as it is a marker of kidney damage and progression of CKD.
Mechanisms of Action
Losartan's renoprotective effects are attributed to its ability to modulate the renin-angiotensin system (RAS). In a study on rats with CKD induced by fructose overload, losartan prevented metabolic and hemodynamic alterations, reduced pro-inflammatory and pro-fibrotic markers, and maintained renal function . This study highlights losartan's role in balancing the RAS and renal dopaminergic system, which is crucial for sodium management and inflammation control.
Losartan in Acute Kidney Injury
Ischemia/Reperfusion Injury
Ischemia/reperfusion (I/R) injury is a common cause of acute kidney injury. Research on male rats indicated that losartan, alone or in combination with angiotensin 1-7, significantly reduced markers of kidney damage such as serum urea nitrogen, creatinine, and malondialdehyde levels after I/R induction . This suggests that losartan can mitigate acute kidney damage by inhibiting the harmful effects of angiotensin II.
Safety and Adverse Effects
While losartan is generally well-tolerated, combination therapy with other RAS inhibitors like ACE inhibitors can increase the risk of adverse events such as hyperkalemia and acute kidney injury. A study on combination therapy with losartan and lisinopril in patients with diabetic nephropathy was halted early due to safety concerns, despite a trend towards renal benefits .
Conclusion
Losartan has demonstrated significant renoprotective effects in various settings, including diabetic nephropathy, chronic kidney disease, and acute kidney injury. It effectively reduces proteinuria, slows the progression of kidney damage, and balances key renal regulatory systems. However, its long-term benefits and safety profile, particularly in combination therapies, require careful consideration. Overall, losartan remains a valuable therapeutic option for preserving kidney health in patients with diabetes and CKD.
Sources and full results
Most relevant research papers on this topic
DOI